Other

Targacept, Inc.

Niranjan Madhukar Deo

Peter Anthony Crooks

Gary Maurice Dull

William Scott Caldwell

Balwinder Singh Bhatti

Alain Ravard

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo&lsqb;2.2.1&rsqb;heptane, a 1-aza-2-(3-pyridyl)bicyclo &lsqb;2.2.2&rsqb;octane, a 1-aza-2-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane, a 1-aza-7-(3-pyridyl) bicyclo&lsqb;2.2.1&rsqb;heptane, a 1-aza-3-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane, or a 1-aza-7-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane.

Pharmaceutical compositions for treating and/or preventing CNS disorders

Pharmaceutical compositions and methods for use

A compound of the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value equal to 0; A, A' and A' are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z' is hydrogen or a substituent other than hydrogen; Y is C.dbd.O, C(OH)R' or C--A, where R' is hydrogen or lower alkyl is provided.

Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.

Pharmaceutical compositions for prevention and treatment of central

Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.

Growing community of inventors

Cincinnati, OH, United States of America

Niranjan Madhukar Deo